Understand the source comparison
5-Amino-1MQ Safe Side Effects: Research vs Speculation Comparison
Preclinical Animal Studies No mortality, organ toxicity, or hepatic/renal dysfunction at 15–50mg/kg daily for 12 weeks in mice Moderate. Reproducible in controlled settings Human metabolism differs; oral bioavailability not tested; thyroid/cardiovascular marke
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Preclinical Animal Studies
- No mortality, organ toxicity, or hepatic/renal dysfunction at 15–50mg/kg daily for 12 weeks in mice
- Moderate. Reproducible in controlled settings
- Human metabolism differs; oral bioavailability not tested; thyroid/cardiovascular markers unmeasured
- University of Florida rodent metabolism studies, intraperitoneal administration
- Anecdotal Human Reports
- Mild nausea (30–40% of users, transient), occasional headaches during week 1, sporadic TSH elevation at 8+ weeks
- Low. No controls, self-reported, inconsistent dosing
- No baseline labs, no follow-up thyroid antibody panels, no long-term tracking
- Research forums, peptide supplier feedback channels
- Mechanism-Based Risk
- NNMT inhibition increases NAD+ in adipose, liver, kidney, brain. Theoretical disruption of sirtuins, PARPs, circadian pathways
- Moderate. Biochemically plausible
- Unknown whether compensatory downregulation occurs; chronic effects on methylation cycles unstudied
- Biochemical pathway analysis from NNMT research
- Long-Term Safety Data
- None. No studies beyond 12 weeks in any species
- N/A
- Cumulative effects, reproductive safety, cardiovascular stress markers, cancer risk all unmeasured
- Absence of Phase 1/2/3 human trials